- Trials with a EudraCT protocol (36)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
36 result(s) found for: Rescue breathing.
Displaying page 1 of 2.
EudraCT Number: 2020-000578-31 | Sponsor Protocol Number: SED002 | Start Date*: 2021-01-14 | |||||||||||||||||||||
Sponsor Name:Sedana Medical AB | |||||||||||||||||||||||
Full Title: A Randomised Active-controlled Study to Compare Efficacy and Safety of Inhaled Isoflurane Delivered by the AnaConDa-S (Anaesthetic Conserving Device) to Intravenous Midazolam for Sedation in Mechan... | |||||||||||||||||||||||
Medical condition: Sedation in Mechanically Ventilated Paediatric Patients 3 to 17 (Less than 18) Years Old | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) SE (Completed) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004551-67 | Sponsor Protocol Number: SED001 | Start Date*: 2017-04-18 |
Sponsor Name:Sedana Medical AB | ||
Full Title: A randomised, controlled, open-label study to confirm the efficacy and safety of sedation with isoflurane in invasively ventilated ICU patients using the AnaConDa administration system | ||
Medical condition: Adult subjects admitted to the ICU clinically indicated to require sedation with propofol and invasive ventilation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) SI (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000702-38 | Sponsor Protocol Number: D3250C00036 | Start Date*: 2017-07-06 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Lon... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002163-26 | Sponsor Protocol Number: D3250C00018 | Start Date*: 2013-11-08 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A multicentre, randomised, double-blind, parallel group, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequatley contr... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002345-11 | Sponsor Protocol Number: D3250C00017 | Start Date*: 2013-10-10 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A multicentre, randomised, double-blind, parallel group, placebo-controlled, Phase III efficacy and safety study of benralizumab (MEDI-563) added to high-dose inhaled corticosteroid plus long-actin... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) CZ (Completed) ES (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002352-32 | Sponsor Protocol Number: D3250C00016 | Start Date*: 2014-02-26 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A multicentre, randomised, double-blind, paralllel group, placebo-controlled, Phase 3 efficacy and safety study of benralizumab (MEDI-563) added to medium dose inhaled corticosteroid plus long acti... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) PL (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000593-19 | Sponsor Protocol Number: D589UC00001 | Start Date*: 2014-08-13 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® pMDI 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuha... | ||
Medical condition: Patients with moderate to very severe chronic obstructive pulmonary disease (COPD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) CZ (Completed) ES (Completed) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013791-49 | Sponsor Protocol Number: RHM MED 0879 | Start Date*: 2009-09-23 | |||||||||||
Sponsor Name:Southampton Universities Hospital Trust | |||||||||||||
Full Title: Safety and Efficacy of parenteral KGF in moderate asthma subjects | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002483-40 | Sponsor Protocol Number: D3741C00007 | Start Date*: 2018-12-05 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, com... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002523-42 | Sponsor Protocol Number: D3250C00020 | Start Date*: 2014-06-24 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A multicenter, randomized, double-blind, parallel group, placebo-controlled, Phase 3 efficacy and safety study of benralizumab (MEDI-563) to reduce oral corticosteroid use in patients with uncontro... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001704-22 | Sponsor Protocol Number: CCD-05993AA1-08 | Start Date*: 2015-02-25 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclometasone dipropionate plus formote... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) PT (Completed) HU (Completed) CZ (Completed) RO (Completed) DK (Completed) DE (Completed) AT (Completed) NO (Completed) PL (Completed) FR (Completed) BG (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003369-20 | Sponsor Protocol Number: CT-P59_3.2 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute R... | |||||||||||||
Medical condition: SARS CoV 2 infection in outpatients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) RO (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006980-22 | Sponsor Protocol Number: TR02-105 | Start Date*: 2007-06-14 | |||||||||||
Sponsor Name:Transave, Inc. | |||||||||||||
Full Title: MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) BE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000337-36 | Sponsor Protocol Number: FSJD-GLUCOBR-2010 | Start Date*: 2011-08-30 | |||||||||||
Sponsor Name:FUNDACIÓ SANT JOAN DE DÉU | |||||||||||||
Full Title: IMPACT OF THE ADMINISTRATION OF SYSTEMIC GLUCOCORTICOIDS ON INFLAMMATORY RESPONSE AND CLINICAL EVOLUTION OF PATIENTS DIAGNOSED WITH MODERATE-SEVERE BRONCHIOLITIS | |||||||||||||
Medical condition: Viral bronchiolitis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004118-37 | Sponsor Protocol Number: CNS7056-026 | Start Date*: 2021-08-31 | |||||||||||
Sponsor Name:PAION UK Ltd [...] | |||||||||||||
Full Title: A Phase 2/3, prospective, open-label trial evaluating the efficacy, safety, and pharmacokinetics of remimazolam for intravenous sedation in paediatric patients undergoing diagnostic and/or therapeu... | |||||||||||||
Medical condition: Paediatric procedural sedation | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002094-36 | Sponsor Protocol Number: D3250C00038 | Start Date*: 2016-11-22 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function with Benralizumab in Severe, U... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001360-21 | Sponsor Protocol Number: CD-RI-CAT-354-1049 | Start Date*: 2011-09-07 | |||||||||||
Sponsor Name:AstraZeneca AB R&D Mölndal | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults with Uncontrolled, Severe Asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001886-33 | Sponsor Protocol Number: MK-8616-076-00 | Start Date*: 2012-10-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: Randomized, Controlled, Parallel Group, Double Blind Trial to Compare the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures Using a 2x2 Fact... | |||||||||||||
Medical condition: Patients undergoing elective in-patient laparoscopic cholecystectomy procedures under general anesthesia with neuromuscular relaxation and active reversal of neuromuscular blockade | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) FI (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001916-20 | Sponsor Protocol Number: 191-079 | Start Date*: 2014-09-18 | |||||||||||
Sponsor Name:Mylan Pharma UK Ltd | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel Group 24 Week Placebo-Controlled Efficacy and Safety Study with a 28 Week Long Term Extension, of Nebulized Fluticasone Propionate (FP) /Formoterol Fumarate (FF... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005919-51 | Sponsor Protocol Number: REP0220 | Start Date*: 2021-01-19 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: A phase 3, double-blind, randomized, placebo-controlled, multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with severe COVID-19 pneumonia. | |||||||||||||
Medical condition: COVID-19 Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
